Corteva (CTVA) Q3 2026 earnings review
Corteva grows outside Latin America, but Brazil slump cuts outlook
In its first report since spinning off its seed division, crop chemical maker Corteva grew in three regions but stumbled in Brazil. Third-quarter sales fell 9% to $1.59 billion as a 31% underlying drop in Latin America wiped out volume gains in North America, Europe and Asia. Chief executive Luke Kissam lowered the full-year profit outlook, and by our math the new plan leaves almost no per-share profit for the fourth quarter.
| Sales from businesses owned a year ago | $1.58B -9% from a year ago (volume -2%, price -7%) |
|---|---|
| Latin America underlying sales | -31% volume -24%, price -7% on Brazil credit crunch |
| Operating EBITDA, excluding one-offs | $222M -17% from a year ago; margin down 1.4 percentage points |
| Full-year profit outlook | Cut Operating EPS $0.76–0.80 vs $0.76 already earned in 9M |
⚖️ Verdict: 🔴 Bearish
The story got worse because chemical price cuts and tight farmer credit in Brazil broke the company's margin expansion streak. Without the spun-off seed business to cushion the blow, a 7% price drop cut third-quarter operating profit by 17% and forced an outlook reduction. One bright spot: farmers outside Latin America bought more of Corteva's newer, patented crop treatments, lifting sales across the rest of the world by 7% by our math.
The question now is whether the Brazil slump is a one-season inventory backup or permanent price erosion from generic competitors. If distributors merely delayed orders because of high interest rates, volumes will recover when credit eases; if generics are taking share, margins will stay under pressure. Fourth-quarter Latin America pricing and distributor inventory levels on the next call will tell.
🐂 Bull Case
New Products Lifted Sales Outside Latin America
"We executed well against the things we can control. New products performed strongly, productivity delivered, and we generated broad-based organic growth outside Latin America," chief executive Luke Kissam said. Corteva sells chemicals and biological treatments that protect farm crops from weeds, insects and disease. Demand for its newer, patented formulas grew across three of its four regions.
- Sales outside Latin America: $1.02 billion, up 7.4% from a year ago by our math
- North America (U.S. and Canada): sales from businesses owned a year ago up 7%, as a 19% volume jump beat lower prices on acetochlor, a weed killer
- EMEA (Europe, Middle East and Africa): underlying sales up 14%, with flat prices
- Asia Pacific: underlying sales up 5%, with volume up 7% and prices down 2%
That regional strength matters because it shows farmers still pay for newer pest and weed treatments even when crop prices are tight. Outside Brazil, higher volumes more than covered chemical price drops.
What to watch: North America and EMEA volumes in the fourth quarter. Continued volume gains there would show that demand for new formulas remains intact heading into the 2027 northern planting season.
Crop Protection Stands Alone After Seed Spin-Off
Corteva completed the spin-off of its seed business, Vylor, and now operates solely as a crop protection company under Kissam. The board authorized the standalone group's first quarterly dividend at $0.05 per share, compared with $0.18 per share for the combined group before the split. Completing the separation on schedule removes the execution uncertainty that hung over the first half of the year.
What to watch: the opening balance sheet in the third-quarter filing. It will show how much of the combined group's $4.88 billion June debt load stayed with the chemical business.
🐻 Bear Case
Brazil Credit Crunch Forced an Outlook Cut
Latin America is Corteva's largest second-half market, and conditions in Brazil deteriorated sharply. "Acetochlor pricing in the U.S. was consistent with our expectations, but Brazil was materially weaker than anticipated," Kissam said. Because of that drop, management lowered its full-year profit outlook.
Sales in Latin America fell 28% to $570 million, or 31% excluding currency and portfolio changes. Volumes dropped 24% because of "elevated channel inventory and delayed purchasing given farmer liquidity constraints and high interest rates", the company said. Regional prices fell another 7% as generic rivals discounted older chemicals.
This hits the thesis hard because Latin America accounted for 45% of third-quarter sales a year ago, and the fourth quarter is the heart of Brazil's planting season. By our math, the updated full-year plan leaves only $169.5 million of operating EBITDA (earnings before interest, taxes, depreciation and amortization, excluding one-offs) for the fourth quarter, and just $0.02 per share of operating profit.
What to watch: fourth-quarter Latin America volumes and the bad-debt provision in the quarterly filing. Another drop in Brazil volumes would mean distributors are still working through unsold stock into 2027.
Chemical Price Cuts Overwhelmed New Product Mix
For the past year, Corteva argued that growing sales of higher-margin new formulas and factory savings would expand its profit margin even while older chemical prices fell. In the first half of 2026, that held true as crop protection margins rose.
In the third quarter, price cuts proved too deep for product mix to cover. Company-wide prices fell 7% from a year ago due to "competitive pressure on molecules late in their lifecycle in Brazil and U.S. acetochlor", the chemical maker said. Total volume also slipped 2%.
As a result, operating EBITDA excluding one-offs fell 17% to $222 million, and the corresponding margin shrank by 1.4 percentage points to 14.0% of sales. On a GAAP basis, the margin after taxes fell 6.8 percentage points into a loss, though the press release did not include the income statement tables showing which cost lines moved.
What to watch: company-wide pricing in the fourth quarter. A price decline near 7% again would show that generic competition on older chemicals is outrunning the margin lift from new products.
Risks This Quarter Didn't Answer
The summary press release omitted balance-sheet and footnote schedules, leaving four standing issues unreadable until the quarterly filing and conference call.
- Customer credit quality in Brazil: allowances for doubtful accounts ($295 million in June) and guaranteed customer loans ($604 million in June) are not in the release; the filing's receivables footnote will show if defaults rose.
- Environmental and PFAS liabilities: no update on the New Jersey settlement or legacy DuPont cost-sharing caps; the filing's legal contingencies note will carry any change.
- Product-line sales breakdown: the release did not split sales by herbicides, insecticides, biologicals or the 'Other' line that jumped in the second quarter; the filing's revenue table will show them.
- Seed royalty income: following the separation, seed licensing economics belong to Vylor and are no longer part of Corteva's results.
👓 Other Themes
Headline Profit Includes Estimated Standalone Cost Savings
Corteva now reports Adjusted Pro Forma Operating EBITDA as its main profit measure after the spin-off. Beyond stripping out restructuring and spin-off costs, this figure includes management's "estimate of certain incremental cost savings associated with operating Corteva as an independent public company" that are not yet in the accounting books. Because the release omitted the reconciliation schedules, investors cannot yet see how much of the $222 million profit came from estimated savings.
💲 Other KPIs
Operating EBITDA excluding one-offs was nearly unchanged over the first nine months, up 0.6% from $937 million a year ago even as sales fell 1% to $5.36 billion. The nine-month profit margin rose 0.3 percentage points to 17.6% because first-half productivity savings and North American volume gains balanced out the third-quarter drop in Brazil.
The company swung to an after-tax GAAP loss of $54 million, or $(0.08) per share, from a profit of $60 million a year ago. For the first nine months, GAAP income fell 68% to $112 million, or $0.16 per share, weighed down by factory restructuring charges, spin-off costs and lower third-quarter chemical prices.
Corteva expects $130 million to $140 million in pre-tax restructuring charges this year for its factory and partner network overhaul, which runs through 2028. That is down slightly from the $140 million to $150 million planned last quarter for the combined group.
🔮 Guidance
Cut. The chemical maker lowered its full-year outlook because Brazil was "resulting in a significantly softer market than previously anticipated". This is the first standalone range after spinning off the seed business. With $943 million earned in the first nine months, the middle of the range leaves $169.5 million for the fourth quarter by our math, down from $222 million in the third quarter.
Cut. Management lowered its full-year per-share profit plan alongside the EBITDA reduction. Because Corteva already earned $0.76 per share across the first nine months, the bottom of the full-year range implies zero profit in the fourth quarter, and the middle of the range leaves $0.02 per share by our math, down from $0.06 in the third quarter.
❓ Key Questions
How much did prior standalone outlook drop on a like-for-like basis?
The company said it updated its full-year outlook for weaker Brazil demand, but prior public targets included the spun-off seed business. Investors need the previous standalone crop protection target to measure the exact size of the fourth-quarter cut.
How big are the estimated standalone cost savings in EBITDA?
Adjusted Pro Forma Operating EBITDA includes management's estimates of incremental cost savings from running as an independent company. Because the release omitted the reconciliation tables, management should quantify how many millions those estimates added to third-quarter and nine-month profit.
Did unpaid farmer bills in Brazil rise during the third quarter?
Management cited farmer liquidity constraints and high interest rates for the 24% volume drop in Latin America. With $604 million of guaranteed customer loans on the books in June, investors need the updated bad-debt provision and past-due receivables in Brazil.
How were debt and environmental liabilities split with Vylor?
Before the spin-off, the combined company carried $4.88 billion in total debt and hundreds of millions in legacy chemical and PFAS environmental accruals. Management needs to detail the opening debt, cash and liability obligations retained by standalone Corteva.